July 14, 2022

Become a licensing partner when developing your LAMP test

Our patent-pending technology contains two innovations: a novel colorimetric detection system that does not depend on changes in pH and LNA-modified LAMP primers that enhance sensitivity and speed. A scientific publication on this technology is currently under review in the prestigious scientific journal Nature Communications.

With the license, you will get the technology we have used for our Vivid COVID-19 LAMP test, which can be easily adapted for the detection of other pathogens as well as nucleic acid biomarkers.

For more information about licensing conditions and how to optimize the development of your LAMP test, see our leaflet, or contact us at info@multiplexdx.com.

About MultiplexDX

MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).

MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.

Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter

Other latest

MultiplexDX News